First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

BACKGROUND: Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC. METHODS: Frail patients without prior advanced colorec...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrato, A., Benavides, M., Massutí, B., Ferreiro-Monteagudo, R., García Alfonso, P., Falcó, E., Reboredo, M., Cano, T., Gallego, J., Viéitez, J. M., Layos, L., Salud, A., Polo, E., Dotor, E., Durán-Ogalla, G., Rodriguez-Garrote, M., Calvo, A., Grande, E., Aranda, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547483/
https://www.ncbi.nlm.nih.gov/pubmed/31159765
http://dx.doi.org/10.1186/s12885-019-5753-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547483/
https://www.ncbi.nlm.nih.gov/pubmed/31159765
http://dx.doi.org/10.1186/s12885-019-5753-7

Ejemplares similares